|
Volumn 333, Issue 6049, 2011, Pages 1560-
|
Novel antibody response may explain HIV vaccine success
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
HUMAN IMMUNODEFICIENCY VIRUS VACCINE;
MEMBRANE PROTEIN;
PLACEBO;
GLYCOPROTEIN GP 120;
HIV ENVELOPE PROTEIN GP120 (135 148);
HIV ENVELOPE PROTEIN GP120 (135-148);
HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;
NEUTRALIZING ANTIBODY;
PEPTIDE FRAGMENT;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ANTIBODY;
BIOCHEMISTRY;
DISEASE CONTROL;
DRUG DEVELOPMENT;
HUMAN IMMUNODEFICIENCY VIRUS;
MEDICINE;
RESEARCH AND DEVELOPMENT;
VACCINE;
ANTIBODY RESPONSE;
ANTIGEN BINDING;
DRUG EFFICACY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNE RESPONSE;
INFECTION PREVENTION;
INFECTION RISK;
PRIORITY JOURNAL;
SHORT SURVEY;
VIRUS NEUTRALIZATION;
ANTIBODY AFFINITY;
ANTIBODY COMBINING SITE;
ANTIBODY SPECIFICITY;
BIOSYNTHESIS;
CLINICAL TRIAL (TOPIC);
HUMAN IMMUNODEFICIENCY VIRUS;
IMMUNOLOGY;
METABOLISM;
NOTE;
THAILAND;
AIDS VACCINES;
ANTIBODIES, NEUTRALIZING;
ANTIBODY AFFINITY;
ANTIBODY SPECIFICITY;
BINDING SITES, ANTIBODY;
CLINICAL TRIALS AS TOPIC;
HIV;
HIV ANTIBODIES;
HIV ENVELOPE PROTEIN GP120;
HIV INFECTIONS;
HUMANS;
PEPTIDE FRAGMENTS;
THAILAND;
|
EID: 80052941706
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.333.6049.1560 Document Type: Short Survey |
Times cited : (12)
|
References (0)
|